abobotulinumtoxinA clinical trials
How each study uses abobotulinumtoxinA is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the abobotulinumtoxinA studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2014 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 5
Galderma R&D (2) · Espad Pharmed (1) · Vanderbilt University Medical Center (1) · David M. Simpson (1) · Neurology Center of New England P.C. (1) · St Joseph University, Beirut, Lebanon (1) · Detroit Clinical Research Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses abobotulinumtoxinA is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Impact of Dysport on PMFF Donor ScarNot yet recruitingPhase 4Vanderbilt University Medical CenterNCT07720726Written as Abobotulinumtoxin-AHow we know
- A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb TremorRecruitingPhase 4David M. SimpsonNCT03136341Written as Abobotulinum toxin AHow we know
- A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar LinesCompletedPhase 3Espad PharmedNCT06946160Written as Abobotulinumtoxin A (Espad Pharmed Darou Co.)How we know
- Safety and Efficacy of Treatment With Azzalure, Restylane/Emervel Filler and Restylane SkinboosterCompletedPhase 4Galderma R&DNCT02297503Written as AzzalureHow we know
- A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar LinesCompletedPhase 4Galderma R&DNCT02108158Written as AzzalureHow we know
- " Treating MS Patients With Lower Extremity Spasticity Using Dysport"Status unknownPhase 3Neurology Center of New England P.C.NCT03585569Written as Abobotulinumtoxin AHow we know
- Frontalis Botulinum ToxinStatus unknownPhase 4St Joseph University, Beirut, LebanonNCT03186001Written as Abobotulinum toxin AHow we know
- Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's SyndromeStatus unknownNot applicableDetroit Clinical Research CenterNCT02187679Written as Abobotulinum toxin AHow we know
Given beside what is tested · 1 — abobotulinumtoxinA is usual care or a partner of the new treatment
Codes
What other systems call abobotulinumtoxinA · ClinicalTrials.gg INT005478
- MeSH (NLM) C542869abobotulinumtoxinAOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C542869 | abobotulinumtoxinA | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.